Experimental Group:Iparomlimab and Tuvonralimab Injection

2 trials

Sponsors

Sichuan Cancer Hospital, Sichuan Provincial People's Hospital

Conditions

Head and Neck Squamous Cell Carcinoma (including cancer of the oral cavity, oropharynx, hypopharynx, larynx, etc.)Triple Negative Breast Cancer (TNBC)

Phase 2

A single arm, single center study to explore the efficacy and safety of Iparomlimab and Tuvonralimab Injection plus Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Active, not recruitingChiCTR2500102974

Sichuan Cancer HospitalTriple Negative Breast Cancer (TNBC)

Start: 2025-06-01Updated: 2025-05-26

Unknown Phase

An Exploratory Study of Iparomlimab/Tuvonralimab (QL1706) Combined with Induction Chemotherapy and Radio(chemo)therapy for the Full-course Treatment of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma

Active, not recruitingChiCTR2500113996

Sichuan Provincial People's HospitalHead and Neck Squamous Cell Carcinoma (including cancer of the oral cavity, oropharynx, hypopharynx, larynx, etc.)

Start: 2025-12-16Updated: 2025-12-08